Taltz vs Rinvoq
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Taltz | US Rinvoq | |
|---|---|---|
| Generic name | ixekizumab | upadacitinib |
| Drug class | IL-17A Inhibitor (Biologic) | JAK Inhibitor |
| Treats | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis | Rheumatoid arthritis, psoriatic arthritis, eczema |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Eli Lilly | AbbVie |
| Year approved | 2016 | 2019 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $190M | $175M |
| Common side effects | Injection site reactions, Respiratory infections, Inflammatory bowel disease, Low white blood cell count | Serious infections, Blood clots, Cardiovascular events, Cancer risk |
Frequently asked questions
Is Taltz or Rinvoq better?
Neither is universally "better." Taltz (ixekizumab) and Rinvoq (upadacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Taltz and Rinvoq?
Taltz is a IL-17A Inhibitor (Biologic) made by Eli Lilly, while Rinvoq is a JAK Inhibitor made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Taltz has the larger estimated TV advertising budget of the two.